XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Note 6 - Realignment of Goals and Objectives and New Development Focus | 12 Months Ended
--- | ---
Dec. 31, 2017
Notes to Financial Statements |
Restructuring and Related Activities Disclosure [Text Block] |
6. | Realignment of Goals and Objectives and New Development Focus
Following the approval of SUSTOL and consistent with our transition into a commercial-stage biotechnology company, we realigned our goals and objectives and refocused our development efforts t o the area of postoperative pain management. On October 18, 2016, we entered into a lease agreement for new office and laboratory space in San Diego, California, which became our corporate headquarters in December 2016. On September 30, 2016, the board of directors accepted the resignations of three executive officers, and these executive officers and other employees directly affected by the realignment and refocusing were, or will be, provided with one -time severance payments on termination, continued benefits for a specified period of time and outplacement assistance. We expect to incur total expenses of $9. 6 million in connection with these activities, $5.7 million of which is primarily for severance and $3.9 million of which is for non-cash, stock-based compensation expense. From September 30, 2016 through December 31, 2017, we have recognized expense of $9.6 million. We expect to make the final payment resulting from the realignment of our goals and objectives and new development focus in the third quarter of 2018. As of December 31, 2017, we have paid $4.6 million of the total $5.7 million cash charges. As of December 31, 2017, the remaining $1.1 million was included in accrued payroll and employee liabilities in the consolidated balance sheets. F or the year ended December 31, 2017, total expenses related to the realignment were $1.8 million, with $1.5 million included in research and development expense and $0.3 million in general and administrative expense. We have accounted for these expenses in accordance with Accounting Standard Codification No. 420, Exit or Disposal Cost Obligations .

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI http://asc.fasb.org/topic&trid=2175745 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration